# Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above

> **NCT07289542** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Suzhou Abogen Biosciences Co., Ltd.** · enrollment: 420 (estimated)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** ABO1105
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07289542
- **Lead sponsor:** Suzhou Abogen Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2026-01-07
- **Final completion:** 2027-10-15
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07289542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07289542, "Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07289542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*